Printer Friendly
The Free Library
19,573,952 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

CHF Solutions, Inc., Completes $22.9 Million Financing; Proceeds to Be Used to Complete UNLOAD Clinical Trial and Expand Marketing Program.


BROOKLYN PARK, Minn. -- CHF CHF

In currencies, this is the abbreviation for the Swiss Franc.

Notes:
The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion.
 Solutions, Inc., a privately held medical device manufacturer, has completed a $22.9 million offering of its convertible, preferred stock Stock shares that have preferential rights to dividends or to amounts distributable on liquidation, or to both, ahead of common shareholders.

Preferred stock is given preference over common stock. Holders of preferred stock receive dividends at a fixed annual rate.
. The company plans to use the proceeds to complete a major clinical trial, called UNLOAD, and expand the marketing program for its Aquadex(TM) System. The largest investors are MPM MPM Multi-Processing Module (Apache)
MPM Manufacturing Process Management
MPM Milwaukee Public Museum
MPM MMW (Millimeter Wave) Power Module
MPM Master of Project Management (degree) 
 Capital and SV Life Sciences (formerly Schroder Ventures Life Sciences). Other investors are Investor Growth Capital, Kaiser Permanente Ventures, Brightstone Capital, and Mason Wells Biomedical bi·o·med·i·cal
adj.
1. Of or relating to biomedicine.

2. Of, relating to, or involving biological, medical, and physical sciences.
, along with several other existing investors. SV Life Sciences led the financing round and both SV Life Sciences and Kaiser Permanente Ventures are new investors in CHF Solutions.

"We are very pleased to have the support of such strong investment firms," said John L. Erb, CHF Solutions chief executive officer. "Their interest in CHF Solutions is a testament to the prospects of the Aquadex System in addressing the profound need for an expedient and cost-effective therapy for fluid-overloaded patients. The UNLOAD clinical trial is a major undertaking, and the data will contribute significantly to our knowledge of the sustained benefits of Aquapheresis therapy. Additional marketing resources will help us bring the Aquadex System to more hospitals and patients who can benefit from this therapy."

"CHF Solutions is an excellent fit with our investment criteria - development-stage companies with exceptionally high-quality management and significant upside potential through proprietary products in fast-growing markets," said James Garvey, SV Life Sciences chief executive officer and managing general partner, who will also join the CHF Board of Directors. "We look forward to working with the CHF Solutions management team."

About Aquapheresis and the Aquadex System

Aquapheresis is an advanced form of ultrafiltration ultrafiltration /ul·tra·fil·tra·tion/ (ul?trah-fil-tra´shun) filtration through a filter capable of removing very minute (ultramicroscopic) particles.

ul·tra·fil·tra·tion
n.
 that can remove up to four liters (one gallon) of excess fluid from the body in eight hours. Unlike some drug-based therapies, Aquapheresis removes this fluid with no clinically significant impact on electrolytes, heart rate or blood chemistry. The procedure is highly automated, easy to use, transportable and can be performed in virtually any clinical setting. Standard catheters inserted into peripheral or central veins connect the patient to the Aquadex System. Recent technological advancements will now allow the therapy to be delivered via standard peripheral IVs, further improving the safety, ease, and convenience of Aquadex therapy.

The Aquadex System is used to perform Aquapheresis(TM). Congestion The condition of a network when there is not enough bandwidth to support the current traffic load.

congestion - When the offered load of a data communication path exceeds the capacity.
, in heart failure patients, results in symptomatic shortness of breath Shortness of Breath Definition

Shortness of breath, or dyspnea, is a feeling of difficult or labored breathing that is out of proportion to the patient's level of physical activity.
, and edema edema (ĭdē`mə), abnormal accumulation of fluid in the body tissues or in the body cavities causing swelling or distention of the affected parts.  of the extremities and abdomen. Heart failure is currently the leading cause of hospitalization in the United States. An estimated five million Americans suffer from the condition resulting in 3.1 million hospital admissions at a cost of more than $23 billion annually. With the aging population, congestive heart failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time.  diagnoses are growing 8 percent annually in the United States. Aquapheresis with the Aquadex System technology received 510(k) marketing clearance in mid-2002 and is currently being used in 52 hospitals across the nation.

About the UNLOAD Trial

The UNLOAD trial (UltrafiltratioN versus IV Diuretics Diuretics Definition

Diuretics are medicines that help reduce the amount of water in the body.
Purpose

Diuretics are used to treat the buildup of excess fluid in the body that occurs with some medical conditions such as congestive heart
 for Patients HospitaLized for Acute Decompensated Congestive Heart Failure) was launched in mid-2004 and is comparing the immediate and long-term safety and efficacy of treatment with the Aquadex System technology to conventional pharmaceutical therapy (i.e. intravenous diuretics) in hospitalized heart failure patients with fluid overload. This prospective, randomized ran·dom·ize  
tr.v. ran·dom·ized, ran·dom·iz·ing, ran·dom·iz·es
To make random in arrangement, especially in order to control the variables in an experiment.
 and controlled study will enroll 200 patients at as many as 30 U.S. clinical sites. Researchers will document patient outcomes during the patient's hospitalization and three months following discharge to demonstrate acute and sustained clinical benefit.

About CHF Solutions

CHF Solutions, based in Brooklyn Park, Minn., is a privately held manufacturer of innovative medical devices for cardiac care. The company's mission is to provide medical practitioners with innovative and practical solutions that enable the treatment of patients with unmet clinical needs. For additional information about CHF Solutions, Aquapheresis, and the Aquadex System, visit www.chfsolutions.com.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jan 19, 2005
Words:634
Previous Article:Polychromix Educates Attendees at Photonics West on the Value of MOEMS for Optical Switching and Wavelength Management Applications.
Next Article:ManTech Donates NetWitness Software to ''SEARCH'' - Non-Profit Organization Dedicated to Improving the Criminal Justice System.
Topics:



Related Articles
Vasomedical Heart Failure Trial Begins.
Effectiveness of the clinical pathway in the management of congestive heart failure. (Review Article).
CHF Solutions Appoints Paul A. Sobotka Chief Medical Officer.
CHF Solutions Initiates Multi-Center Clinical Trial of Aquapheresis Therapy.
CHF Solutions Clinical Results Presented at the Scientific Meeting of the Heart Failure Society of America.
CHF Solutions Names Michael S. Gebauer Vice President of Marketing.
CHF Solutions Launches Aquadex FlexFlow Fluid Removal System.
CHF Solutions Named One of 50 Companies to Watch by Medical Device & Diagnostic Industry Magazine.
CHF Solutions Names David B. Springer President and Chief Operating Officer; Executive to Focus on Building Sales for Innovative Heart Failure...
CHF Solutions Promotes David B. Springer to President and Chief Executive Officer, and Ronald M. Nelson to Chief Financial Officer.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles